<DOC>
	<DOCNO>NCT02998385</DOCNO>
	<brief_summary>A phase III , multicenter , randomize , open-label , french study comparing : - Arm A : Radiotherapy alone ( 66 70 Gy ; 5 fractions/week ; 1fraction/day ; 2 Gy/fraction ) - Arm B : Radiotherapy ( 66 70 Gy ; 5 fractions/week ; 1fraction/day ; 2 Gy/fraction ) + concomitant cisplatin 100 mg/m2 IV day 1 - J22 - 43 ( 3 cycle )</brief_summary>
	<brief_title>Chemo-radiotherapy Versus Radiotherapy Treatment Salivary Glands Nasal Tumors</brief_title>
	<detailed_description>Carcinomas sinuses salivary gland rare . They heterogeneous term anatomical site histology subtypes . For reason absence prospective study , treatment still largely extrapolate data frequent carcinoma upper digestive tract . These tumor often diagnose lately . Their treatment base multimodal management care , central place surgery radiotherapy ( Proof level Grade C ) . Despite advance surgical technique , addition radiation therapy , 5-year overall survival probability exceed 65 % mainly due loco regional development . In context , chemotherapy administer concomitantly radiotherapy , could increase efficacy locoregional treatment radiosensibilization process regardless histology . This point regularly discuss multidisciplinary concertation meeting , include bi-monthly national REFCOR meeting ( network French Expertise rare Cancers head neck ) . At present , lack data brings even discuss addition cisplatin exclusive irradiation unresectable operable tumor . No randomized study publish context . The first comparative prospective study address addition weekly cisplatin adjuvant irradiation salivary , phase II randomize study ( Radiation Therapy Oncology Group - RTOG 1008 ) currently enrol patient United States America . The Sponsor propose conduct phase III randomize study evaluate impact addition cisplatin treatment radiotherapy adjuvant setting ( ≥ 65 Gy ) case high risk recurrence : case radioresistant histology ( e.g . cystic fibrosis adenoid carcinoma ) , case unfavourable histo-prognostic criterion ( incomplete resection , presence embolus , etc . ) population .</detailed_description>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Resected tumor sinus salivary gland T34 , N13 T12 N0 , overgrown bank positive margin ( &lt; 5 mm ) Unresectable operable tumor salivary gland sinuses Carcinomas major salivary gland ( Parotid , submandibular sublingual gland ) accessory follow histology : adenoid cystic Carcinoma , adenocarcinoma without another indication ( SAI ) highgrade , mucoepidermoid intermediate grade high grade Carcinoma , salivary ductal carcinoma , carcinoma turn cell ( dedifferencie contingent Ki 67 &gt; 10 % ) , Sebaceous Carcinoma , large cell carcinoma , small cell carcinomas Mucinous adenocarcinoma , carcinoma massively invasive Pleomorphic adenoma , oncocytic carcinoma , myoepithelial Carcinoma Malignant tumor sinus follow histology : adenocarcinoma ethmoid ( ADE ) bowel intestinal type , CF adenoids carcinoma carcinoma salivary origin ( COS ) . Age ≥ 18 year Performance status 0 2 ( WHO criteria ) For patient ≥ 70 year , score G8 questionnaire must &gt; 14 fall previous 12 month geriatric assessment consistent administration chemotherapy Estimated life expectancy great equal 6 month Neutrophils &gt; 1.5 x 109/l , platelet &gt; 100 x 109/l , hemoglobin ≥ 9.5 g/dl , bilirubin ≤ 3 x upper normal value ( ULN ) , AST/ALT &lt; 5 ULN , PAL &lt; 3 ULN Creatinin Clearance ≥ 60 mL/min Adequate cardiac function accord investigator , compatible administration cisplatin 100 mg/m² Affiliation social insurance beneficiary regimen Patient give write consent sign study specific procedure . History radiation therapy ENT area Synchronous metastasis Contraindications administration cisplatin carboplatin Allergy cisplatin and/or excipients Melanoma , lymphoma , tumor mesenchymal ( type Sarcoma ) , epidermoid carcinoma , ( SCUNC ) neuroendocrine carcinomas carcinoma undifferentiated ( SNUC ) , nasopharyngeal carcinoma type 1 , 2 , 3 . Vaccination yellow fever , recent plan Administration phenytoin prophylactic purpose Other cancer , except cancer situ cervix , skin Carcinoma ( except melanoma ) cancer control 5 year Pregnant , breastfeed without birth control woman . Woman ability procreate ( serum urinary ) negative pregnancy test within 14 day prior study treatment decisionmaking . ( Men woman ) patient use reliable contraceptive method throughout treatment least 6 month end chemotherapy . Persons deprive liberty supervision curatorship , unable adhere medical followup study geographical , social psychological reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>salivary gland</keyword>
	<keyword>sinus carcinoma</keyword>
	<keyword>radiochemotherapy concomitant</keyword>
	<keyword>cisplatin</keyword>
</DOC>